Opexa Goes Into Hold Mode, Awaiting Secondary Progressive MS Data
This article was originally published in The Pink Sheet Daily
Biotech cuts staff by 30%, hoping for good news from Phase IIb trial due in the fourth quarter. Status of second candidate nearing the clinic is uncertain.
Register for our free email digests: